Hoth Therapeutics Reports Data For HT-001; No Serious Adverse Events

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations.